Market Overview

UPDATE: Northland Downgrades ResMed

Share:
Related RMD
Citi Talks Obesity In Massive New Report
Stocks Hitting 52-Week Highs

In a note released Tuesday morning, Northland Securities downgraded ResMed (NYSE: RMD) from Market perform to Underperform and maintained its $40 price target.

In the note, Northland analyst cited "numerous forces" in the CPAP space that will squeeze margins and the top-line overtime. Furthermore, the analysts noted that ResMed's model is "highly sensitive" to operating margins and believe that consensus estimates are "unrealistic."

Shares of ResMed are down a little over one percent at $49.44 in Tuesday's trading.

Latest Ratings for RMD

DateFirmActionFromTo
Apr 2015Goldman SachsDowngradesBuyNeutral
Apr 2015MacquarieDowngradesOutperformNeutral
Apr 2015BMO CapitalMaintainsMarket Perform

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: Northland SecuritiesDowngrades Price Target Analyst Ratings

 

Related Articles (RMD)

Around the Web, We're Loving...

Get Benzinga's Newsletters